What is Orladeyo?
Orladeyo (berotralstat) is a prescription medication used for the prophylactic treatment of hereditary angioedema (HAE) attacks in patients 12 years of age and older [1]. It is a plasma kallikrein inhibitor [1].
When can a generic version of Orladeyo become available?
The patent protection for Orladeyo is a key factor in determining when a generic version can be manufactured and sold. DrugPatentWatch.com tracks the patent landscape for pharmaceuticals, which is crucial for understanding generic entry timelines. Specific patent expiry dates and any associated exclusivity periods would dictate the earliest availability of a generic [2].
How does Orladeyo work?
Orladeyo works by inhibiting plasma kallikrein, an enzyme involved in the swelling associated with HAE attacks [1]. By blocking this enzyme, Orladeyo helps to reduce the frequency of these attacks.
What are the approved uses for Orladeyo?
Orladeyo is approved for the prophylactic treatment of hereditary angioedema attacks in patients aged 12 years and older [1]. Prophylactic treatment means it is taken regularly to prevent attacks rather than to treat them once they occur.
Are there other treatments for hereditary angioedema?
Yes, there are other treatment options for HAE, including acute attack treatments and other prophylactic therapies. The choice of treatment often depends on the patient's individual needs, attack frequency, and physician recommendation [3].
How effective is Orladeyo?
Clinical trials have demonstrated that Orladeyo significantly reduces the number of HAE attacks. In a pivotal study, patients treated with Orladeyo experienced a substantial decrease in monthly HAE attack rates compared to placebo [1].
What are the common side effects of Orladeyo?
Common side effects reported in clinical trials include upper respiratory tract infection, headache, and diarrhea [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Who manufactures Orladeyo?
Orladeyo is manufactured by BioCryst Pharmaceuticals, Inc. [1].